Australia Biologics Market Size & Outlook, 2026-2033
The biologics market in Australia is expected to reach a projected revenue of US$ 24,042.8 million by 2033. A compound annual growth rate of 9.3% is expected of Australia biologics market from 2026 to 2033.
Revenue, 2025 (US$M)
$11,716.8
Estimate, 2026 (US$M)
$12,893.7
Forecast, 2033 (US$M)
$24,042.8
CAGR, 2026 - 2033
9.3%
Global Market
Related Markets
Australia biologics market highlights
- The Australia biologics market generated a revenue of USD 11,716.8 million in 2025 and is expected to reach USD 24,042.8 million by 2033.
- The Australia market is expected to grow at a CAGR of 9.3% from 2026 to 2033.
- In terms of segment, microbial was the largest revenue generating source in 2025.
- Microbial is the most lucrative source segment registering the fastest growth during the forecast period.
Biologics market data book summary
| Market revenue in 2025 | USD 11,716.8 million |
| Market revenue in 2033 | USD 24,042.8 million |
| Growth rate | 9.3% (CAGR from 2026 to 2033) |
| Largest segment | Microbial |
| Fastest growing segment | Microbial |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Microbial, Mammalian |
| Key market players worldwide | Samsung BioLogics, Amgen Inc, Novo Nordisk A/S ADR, AbbVie Inc, Sanofi SA, Johnson & Johnson, Celltrion Healthcare, Bristol-Myers Squibb Co, Eli Lilly and Co, Roche Holding AG ADR |
Other key industry trends
- In terms of revenue, Australia accounted for 1.9% of the global biologics market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, Japan biologics market is projected to lead the regional market in terms of revenue in 2033.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 51,059.6 million by 2033.
No credit card required*
Publish Date: Jun 11, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Biologics Market Scope
Biologics Market segmentation & scope
Others
Biologics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Johnson & Johnson | View profile | 134,400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | www.jnj.com |
| Amgen Inc | View profile | 26,700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | www.amgen.com |
| Roche Holding AG ADR | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| Eli Lilly and Co | View profile | 43,000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | www.lilly.com |
| Novo Nordisk A/S ADR | View profile | 66,015 | Novo Alle 1, Bagsvaerd, Denmark, 2880 | www.novonordisk.com |
| Samsung BioLogics | View profile | 1001-5000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | www.samsungbiologics.com/ |
| Celltrion Healthcare | View profile | 51-100 | Incheon, Inch'on-jikhalsi, South Korea, Asia | www.celltrionhealthcare.com/ |
Australia Biologics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Biologics Market Outlook will help companies and investors design strategic landscapes.
Microbial was the largest segment with a revenue share of 64.16% in 2025.
Horizon Databook has segmented the Australia biologics market based on microbial, mammalian covering the revenue growth of each sub-segment from 2021 to 2033.
- Australia Biologics Market Source Outlook (Revenue, USD Million , 2021-2033)
- Microbial
- Mammalian
- Others
- Australia Biologics Market Product Outlook (Revenue, USD Million , 2021-2033)
- Monoclonal antibodies (MABs)
- Vaccines
- Recombinant Proteins
- Antisense & RNAi Therapeutics
- Others
- Australia Biologics Market Disease Category Outlook (Revenue, USD Million , 2021-2033)
- Oncology
- Infectious Diseases
- Immunological Disorders
- Cardiovascular Disorders
- Haematological Disorders
- Others
- Australia Biologics Market Manufacturing Outlook (Revenue, USD Million , 2021-2033)
- In-house
- Outsourced
Reasons to subscribe to Biologics Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Biologics Market Outlook databook
- Our clientele includes a mix of Biologics Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia Biologics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Australia Biologics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Australia Biologics Market, 2021-2033 (US$M)
Australia Source - Biologics Market Statistics, 2025 - 2033 (US$M)
Related industry reports
No Records
No related reports found.
Related statistics
No Records
No related statistics found.